Circassia Pharmaceuticals Plc Result of AGM (7881U)

TIDMCIR

RNS Number : 7881U

Circassia Pharmaceuticals Plc

16 July 2018

16 July 2018

Circassia Pharmaceuticals plc

Result of General Meeting

Further to the announcement made on 27 June 2018 by Circassia Pharmaceuticals plc ("Circassia" or "the Company") (LSE: CIR) regarding the publication of a Circular containing a Notice of General Meeting of the Company's shareholders, the Company announces that the Special Resolution contained in the Circular was duly passed at a general meeting of the Company held today. The result of the poll in relation to the Special Resolution was as follows:

 
 Special Resolution                          For           %       Against   %     Withheld* 
      To: 
       (i) approve the related-party 
       transaction with AstraZeneca 
       and implement the terms 
       of the Amendment Letter 
       and give effect to the proposed 
       amendments to the DCA; 
       (ii) issue and allot Ordinary 
       Shares up to an aggregate 
       nominal amount of GBP18,980.64; 
       and 
       (iii) disapply the pre-emption 
       rights that would otherwise 
       apply in respect of the 
       issuance and allotment of 
       Ordinary Shares to AstraZeneca 
       in connection with the Transaction    233,507,567   100.0   2,839     0.0   5,673 
                                            ------------  ------  --------  ----  ---------- 
 

* A vote withheld is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

As such, an application has been made to the UK Listing Authority and the London Stock Exchange for 23,725,800 ordinary shares of 0.08 pence each in the Company ("Ordinary Shares") to be admitted to the premium listing segment of the Official List of the UK Listing Authority and to trading on the London Stock Exchange's main market for listed securities (together, "Admission"). It is expected that Admission will become effective at 08:00 a.m. on 17 July 2018. When issued, the Ordinary Shares will rank pari passu with the existing Ordinary Shares of the Company.

Capitalised terms herein shall have the definitions given to them in the Circular dated 27 June 2018 (the "Circular") unless where otherwise stated. The full text of the resolution is shown in the Notice of General Meeting set out in the Circular.

In accordance with LR 9.6.2, a copy of the resolutions passed at today's General Meeting will be submitted to the National Storage Mechanism and will be shortly available for inspection at www.morningstar.co.uk/uk/NSM.

A copy of this announcement will be posted on the company's website, www.circassia.com.

For further information, please contact:

Circassia Pharmaceuticals plc

Julien Cotta, Company Secretary [phone]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

RAGSFIFLMFASEEW

(END) Dow Jones Newswires

July 16, 2018 10:28 ET (14:28 GMT)